DK2362725T3 - Antivirale supplement-formuleringer - Google Patents

Antivirale supplement-formuleringer Download PDF

Info

Publication number
DK2362725T3
DK2362725T3 DK09825263T DK09825263T DK2362725T3 DK 2362725 T3 DK2362725 T3 DK 2362725T3 DK 09825263 T DK09825263 T DK 09825263T DK 09825263 T DK09825263 T DK 09825263T DK 2362725 T3 DK2362725 T3 DK 2362725T3
Authority
DK
Denmark
Prior art keywords
approx
composition
influenza
lysine
ascorbate
Prior art date
Application number
DK09825263T
Other languages
English (en)
Inventor
Kenneth E Phillips
Cynthia A Winning
Original Assignee
Vymedic Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vymedic Llc filed Critical Vymedic Llc
Application granted granted Critical
Publication of DK2362725T3 publication Critical patent/DK2362725T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (13)

1. Terapeutisk effektiv mængde af en oral antiviral supplement-sammensætning til anvendelse i behandlingen af eller som profylakse af influenza A, influenza B, influenza C en ikke-polio-enterovirusinfektion hos et individ med behov derfor, hvor sammensætningen omfatter lysin, en ascorbinsyreforbindelse, et flavonoidglycosid, en threonin, en taurin og en pyridoxin.
2. Sammensætningen ifølge krav 1, hvor lysin er valgt fra L-lysin, L-lysin-monohydrochlorid, L-lysin-dihydrochlorid, L-lysin-succinat, L-lysin-glutamat, og L-lysin-orotat.
3. Sammensætningen ifølge krav 1 eller krav 2, hvor ascorbinsyreforbindelsen er valgt fra én eller flere af ascorbinsyre, calciumascorbat, magnesiumascorbat, kaliumascorbat,natriumascorbat, manganascorbat, zincascorbat, jernascorbat, kobberascorbat, borascorbat, molybdænascorbat, chromascorbat, ascorbylpalmitat, ascorbylarachidonat, ascorbylstearat, ascorbyllinoleat, ascorbyllinoleneat, og ascorbyloleat.
4. Sammensætningen ifølge et hvilket som helst af kravene 1 til 3, hvor flavonoidglycosidet er valgt fra én eller flere af hesperidin, rutin, naringin, og quercitrin.
5. Sammensætningen ifølge et hvilket som helst af kravene 1 til 4, hvor flavonoidglycosidet er ca. en l:l-blanding ved vægt af hesperidin og rutin.
6. Sammensætningen ifølge et hvilket som helst af kravene 1 til 5, hvor pyridoxinet er pyridoxin-hydrochlorid.
7. Sammensætningen ifølge et hvilket som helst af kravene 1 til 6, hvor sammensætningen er i en form valgt fra gruppen bestående af pulver, kapsel, bolsje, pastil, tablet, væske, eller caplet.
8. Sammensætningen ifølge et hvilket som helst af kravene 1 til 3 omfattende L-lysin-monohydrochlorid, ascorbinsyre, hesperidin, rutin, pyridoxin-hydrochlorid, threonin, og taurin.
9. Sammensætningen ifølge krav 8 yderligere omfattende calciumascorbat, niacinamidascorbat, og ascorbylpalmitat.
10. Sammensætningen ifølge krav 8, hvor en enkelt dosis omfatter fra ca. 2 g til ca. 3,5 g L-lysin-monohydrochlorid; fra ca. 0,1 g til ca. 1,5 g ascorbinsyre; fra ca. 0,2 g til ca. 0,8 g hesperidin; fra ca. 0,1 g til ca. 0,5 g rutin; fra ca. 0,04 g til ca. 0,08 g pyridoxin-hydrochlorid; fra ca. 0,01 g til ca. 0,08 g threonin; og fra ca. 0,02 g til ca. 0,4 g taurin.
11. Sammensætningen ifølge krav 10 yderligere omfattende fra ca. 0,5 g til ca. 0,75 g calciumascorbat; fra ca. 0,1 g til ca. 0,5 g niacinamidascorbat; og fra ca. 0,01 g til ca. 0,1 g ascorbylpalmitat.
12. Sammensætningen ifølge krav 10, hvor den enkelte dosis omfatter ca. 3 g L-lysin-monohydrochlorid; fra ca. 0,2 g til ca. 1,0 g ascorbinsyre; ca. 0,3 g hesperidin; ca. 0,3 g rutin; ca. 0,05 g pyridoxin-hydrochlorid; ca. 0,05 g threonin; og fra ca. 0,02 g til ca. 0,3 g taurin.
13. Sammensætningen ifølge krav 12 yderligere omfattende ca. 0,6 g calciumascorbat; 0,3 g niacinamidascorbat, og ca. 0,05 g ascorbylpalmitat.
DK09825263T 2008-11-04 2009-10-30 Antivirale supplement-formuleringer DK2362725T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11123408P 2008-11-04 2008-11-04
PCT/US2009/062673 WO2010053833A1 (en) 2008-11-04 2009-10-30 Antiviral supplement formulations

Publications (1)

Publication Number Publication Date
DK2362725T3 true DK2362725T3 (da) 2015-03-23

Family

ID=42132167

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09825263T DK2362725T3 (da) 2008-11-04 2009-10-30 Antivirale supplement-formuleringer

Country Status (8)

Country Link
US (6) US9034834B2 (da)
EP (1) EP2362725B1 (da)
CN (1) CN102264222B (da)
CA (2) CA2742302C (da)
DK (1) DK2362725T3 (da)
ES (1) ES2534245T3 (da)
MX (1) MX2011004678A (da)
WO (1) WO2010053833A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2742302C (en) * 2008-11-04 2018-01-02 Vymedic, Llc Antiviral supplement formulations
US20120093738A1 (en) * 2009-06-11 2012-04-19 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
US9616124B2 (en) 2014-07-17 2017-04-11 Jonathan S. Nimitz Antiviral supplement compositions and methods of use
JP5796863B1 (ja) * 2014-10-31 2015-10-21 節郎 山田 腫瘍検査用組成物及び腫瘍検査用試験紙
EP3934357B1 (en) 2016-08-11 2024-05-15 Samsung Electronics Co., Ltd. Method and apparatus of data transmission in next generation cellular networks
TWI761672B (zh) 2018-04-23 2022-04-21 日商阿爾卑斯藥品工業股份有限公司 O-醣苷基類黃酮之組成物
US12227434B2 (en) * 2018-07-10 2025-02-18 Louise Wilkie Humic and fulvic black water based beverage for human consumption
US10918654B1 (en) * 2019-09-23 2021-02-16 Alps Pharmaceutical Ind. Co., Ltd. Rutin compositions
FR3101540B1 (fr) * 2019-10-04 2023-06-02 Urgo Rech Innovation Et Developpement Produit de combinaison pour soulager les bronches et faciliter l’endormissement
US20210275446A1 (en) * 2020-03-03 2021-09-09 Morou Boukari Method of treating a viral infection
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
WO2022094126A1 (en) * 2020-10-29 2022-05-05 Jager Rama D Pharmacological compositions for the treatment and prevention of coronavirus disease
US20250032423A1 (en) * 2023-07-25 2025-01-30 Edhas Technologies Inc. Herbal bioactives based immunostimulant formulation for poultry birds & cattle and preparation thereof
WO2025038636A1 (en) 2023-08-14 2025-02-20 Vymedic, Inc. Antiviral supplement formulations for herpesvirus infections

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424232A (en) 1982-05-19 1984-01-03 Parkinson Richard W Treatment of herpes simplex
US5278189A (en) 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5650418A (en) 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
WO1992015315A1 (en) * 1991-03-06 1992-09-17 Wilkinson Alfred H B Method for the treatment of herpes
EP0625312B1 (en) 1992-11-10 1999-03-03 Otsuka Pharmaceutical Co., Ltd. Feeding composition
US5626883A (en) 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
US5719133A (en) * 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
AT405477B (de) 1996-04-03 1999-08-25 Norbert Mag Fuchs Kombinationspräparat
AU6141498A (en) * 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
DE19809304A1 (de) 1998-03-05 1999-09-09 Merck Patent Gmbh Formulierungen mit antiviraler Wirkung
AU3731699A (en) 1998-05-18 1999-12-06 Takeda Chemical Industries Ltd. Orally disintegrable tablets
US6316008B1 (en) 1998-09-03 2001-11-13 John C. Godfrey Combination of zinc ions and vitamin C and method of making
US6231889B1 (en) 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
KR100363180B1 (ko) * 1998-10-20 2003-01-24 한국과학기술연구원 바이오플라보노이드계화합물을포함하는혈청고밀도지단백질증가용조성물
US6362225B1 (en) 1999-01-21 2002-03-26 George Andreakos Target therapies for treating common viral infections
ATE257332T1 (de) * 1999-03-18 2004-01-15 Bristol Myers Squibb Co Vitamin formulierung für kardiovaskuläre gesundheit
US6352712B1 (en) * 1999-04-30 2002-03-05 Daniel O. Lukaczer Dietary supplements for treating fatigue-related syndromes
MXPA02003882A (es) * 1999-10-19 2002-10-23 Procter & Gamble Composiciones para la prevencion y tratamiento de sintomas similares al resfriado y la influenza y sus metodos de uso.
US7115297B2 (en) 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
AU2002236527A1 (en) 2000-11-30 2002-06-11 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
CH694549A5 (de) 2001-01-16 2005-03-31 Dr Matthias Rath Verwendung einer synergistischen Zusammensetzung, die Ascorbat und Lysin für Zustände enthält zur Behandlung extrazellularer Matrixdegeration.
US20040220118A1 (en) * 2001-02-02 2004-11-04 Bland Jeffrey S. Medical composition for balancing bodily processes
US6939860B2 (en) 2002-01-08 2005-09-06 Matthias Rath Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
PL215159B1 (pl) 2002-01-11 2013-10-31 Matthias Rath Odzywcza kompozycja farmaceutyczna uzyteczna w leczeniu raka oraz jej zastosowanie
US20040067890A1 (en) * 2002-10-04 2004-04-08 Gupta Shyam K. Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions
RU2217141C1 (ru) * 2002-11-20 2003-11-27 Балавадзе Михаил Элизбарович Состав "витализин-1" для профилактики атеросклероза, сердечно-сосудистых заболеваний и поддерживающей терапии вирусных заболеваний
RU2217138C1 (ru) * 2002-11-20 2003-11-27 Балавадзе Михаил Элизбарович Состав "витализин-2" для профилактики атеросклероза, сердечно-сосудистых заболеваний и поддерживающей терапии вирусных заболеваний
WO2004093824A2 (en) * 2003-04-08 2004-11-04 Fairfield Clinical Trials, Llc Peri-operative and peri-procedure nutritional supplementation
ZA200402741B (en) * 2003-04-10 2004-10-26 Janse Van Rensburg And Timothy Supplements for HIV infected persons.
CN1650911A (zh) * 2004-02-03 2005-08-10 肖自力 复合银杏口香糖、含片、咀嚼片及制作方法
US20060088574A1 (en) * 2004-10-25 2006-04-27 Manning Paul B Nutritional supplements
ITMI20052204A1 (it) 2005-11-18 2007-05-19 Umberto Cornelli Uso di colostro per la profilassi delle sindroni influenzali
CN1813779A (zh) * 2005-11-23 2006-08-09 中山大学 柚皮苷在制备防治流感药物中的应用
US7790203B2 (en) * 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
JP2007215507A (ja) * 2006-02-17 2007-08-30 Kobayashi Pharmaceut Co Ltd スピルリナおよびクロレラ含有食品組成物
US20070212426A1 (en) 2006-03-10 2007-09-13 Matthias Rath Composition and method of retarding viral activity and reducing viral replication
US20080038367A1 (en) * 2006-08-11 2008-02-14 Sal Saloum Nutritional supplement compositions and methods of preparing
CA2742302C (en) * 2008-11-04 2018-01-02 Vymedic, Llc Antiviral supplement formulations

Also Published As

Publication number Publication date
US11224606B2 (en) 2022-01-18
US20100113373A1 (en) 2010-05-06
US20150272974A1 (en) 2015-10-01
CA2977492C (en) 2019-03-12
US20180256618A1 (en) 2018-09-13
EP2362725A4 (en) 2012-05-23
US9034834B2 (en) 2015-05-19
CA2977492A1 (en) 2010-05-14
CA2742302C (en) 2018-01-02
ES2534245T3 (es) 2015-04-20
US20240075048A1 (en) 2024-03-07
WO2010053833A1 (en) 2010-05-14
US20220323469A1 (en) 2022-10-13
US10478447B2 (en) 2019-11-19
CA2742302A1 (en) 2010-05-14
US9907809B2 (en) 2018-03-06
CN102264222B (zh) 2014-12-10
MX2011004678A (es) 2011-10-11
EP2362725B1 (en) 2015-01-07
US11826377B2 (en) 2023-11-28
EP2362725A1 (en) 2011-09-07
HK1164056A1 (en) 2012-09-21
CN102264222A (zh) 2011-11-30
US20200108086A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
US11826377B2 (en) Antiviral supplement formulations
EP3110507B1 (en) Compositions and methods for the reduction or prevention of hepatic steatosis
US20230210930A1 (en) Compositions and methods for treating depression
WO2018058109A1 (en) Compositions and methods for treating metabolic disorders
HK1164056B (en) Antiviral supplement formulations
US20230346735A1 (en) Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal
CN116847854A (zh) 包含岩藻糖基乳糖作为有效成分的抗病毒组合物
US20250057865A1 (en) Antiviral supplement formulations for herpesvirus infections
CN104857007A (zh) 一种流感病毒神经氨酸酶的新型抑制剂及其用途
EP4431099A1 (en) Composition containing taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient for preventing or treating viral infectious diseases
KR20210132581A (ko) 폴리포스페이트를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물
JP2018526444A (ja) ウイルス感染症を治療および予防するための組成物